Fabhalta (iptacopan) — NDA/BLA submission
2026
Full data will be presented at future medical meetings and included in regulatory submissions in 2026.Source filing
NVS biotech catalysts & pipeline
NOVARTIS AG · Data as of 2026-10-25
Upcoming catalysts
Rhapsido (remibrutinib) — Clinical data readout
2026
Full study readout and submission for the remaining two subtypes of CINDU expected in 2026.Source filing
ianalumab — NDA/BLA submission
2027
Data presented at ASH, simultaneously published in NEJM, and will be included in regulatory submissions in 2027.Source filing
Zigakibart — Clinical data readout
H1 2027
Zigakibart is currently being evaluated in the Phase III BEYOND study in adults with IgAN, with readout anticipated in H1 2027.Source filing